Discovery of Sphingosine Kinase Inhibition by Modified Quinoline-5,8-Diones

Ryan D Kruschel1, Kyle Malone2, Alison N Walsh1

  • 1School of Chemistry and ABCRF, University College Cork, Western Road, T12K8AF Cork, Ireland.

PubMed

Insights

Researchers developed novel quinoline-5,8-dione compounds as sphingosine kinase (SphK) inhibitors. These compounds show low micromolar dual SphK1/2 inhibition, offering a new avenue for cancer drug development.

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Biochemistry

Background:

  • Sphingosine kinase (SphK) is overexpressed in various cancers, promoting tumor growth.
  • SphK inhibitors are pursued for cancer therapy, with some showing clinical efficacy.
  • Existing inhibitors like PF-543 and opaganib highlight SphK as a drug target.

Purpose of the Study:

  • To develop the first quinoline-5,8-dione-based sphingosine kinase inhibitor.
  • To explore structure-activity relationships for SphK inhibition using a fragment-based approach.
  • To identify novel compounds with potential anticancer properties by targeting SphK.

Main Methods:

  • Fragment-based drug design utilizing CB5468139 and PF-543 as structural leads.
  • Synthesis and characterization of novel quinoline-5,8-dione derivatives.
  • In vitro enzymatic assays against SphK1 and SphK2, and molecular docking studies.

Main Results:

  • Eight novel C(7) ether-linked quinoline-5,8-diones were synthesized and screened for SphK1/2 activity.
  • Pyrrolidine-based derivatives, particularly compound 21, showed improved SphK1 binding efficacy.
  • Molecular modeling indicated favorable docking and binding energies for the pyrrolidine quinoline-5,8-dione scaffold.

Conclusions:

  • First-in-class quinoline-5,8-dione-based SphK inhibitors were identified with low micromolar dual SphK1/2 inhibition.
  • A potential new binding mode for SphK inhibitors was elucidated.
  • While anticancer activity screening was inconclusive, the identified inhibitors represent a promising new chemical framework for further drug development.